Tags

Type your tag names separated by a space and hit enter

COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
Neurol Neurochir Pol. 2021; 55(1):8-11.NN

Abstract

A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only.

Authors+Show Affiliations

Department of Neurology, Medical University of Warsaw, Warsaw, Poland.Poznan University of Medical Sciences, Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan, Poland. akalinowskalyszczarz@ump.edu.pl.Department of Neurology, Zabrze; Medical University of Silesia, Katowice, Poland.Department of Neurology, Medical University of Bialystok, Poland.Department of Neurology, Medical Faculty, University of Rzeszow, Poland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33555604

Citation

Nojszewska, Monika, et al. "COVID-19 mRNA Vaccines (Pfizer-BioNTech and Moderna) in Patients With Multiple Sclerosis: a Statement By a Working Group Convened By the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society." Neurologia I Neurochirurgia Polska, vol. 55, no. 1, 2021, pp. 8-11.
Nojszewska M, Kalinowska A, Adamczyk-Sowa M, et al. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol. 2021;55(1):8-11.
Nojszewska, M., Kalinowska, A., Adamczyk-Sowa, M., Kułakowska, A., & Bartosik-Psujek, H. (2021). COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurologia I Neurochirurgia Polska, 55(1), 8-11. https://doi.org/10.5603/PJNNS.a2021.0016
Nojszewska M, et al. COVID-19 mRNA Vaccines (Pfizer-BioNTech and Moderna) in Patients With Multiple Sclerosis: a Statement By a Working Group Convened By the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. Neurol Neurochir Pol. 2021;55(1):8-11. PubMed PMID: 33555604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. AU - Nojszewska,Monika, AU - Kalinowska,Alicja, AU - Adamczyk-Sowa,Monika, AU - Kułakowska,Alina, AU - Bartosik-Psujek,Halina, Y1 - 2021/02/08/ PY - 2021/01/18/received PY - 2021/01/25/accepted PY - 2021/2/9/pubmed PY - 2021/3/16/medline PY - 2021/2/8/entrez KW - COVID-19 KW - SARS-CoV-2 KW - guidelines KW - multiple sclerosis KW - vaccines SP - 8 EP - 11 JF - Neurologia i neurochirurgia polska JO - Neurol Neurochir Pol VL - 55 IS - 1 N2 - A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only. SN - 0028-3843 UR - https://www.unboundmedicine.com/medline/citation/33555604/COVID_19_mRNA_vaccines__Pfizer_BioNTech_and_Moderna__in_patients_with_multiple_sclerosis:_a_statement_by_a_working_group_convened_by_the_Section_of_Multiple_Sclerosis_and_Neuroimmunology_of_the_Polish_Neurological_Society_ L2 - https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/72921 DB - PRIME DP - Unbound Medicine ER -